265 related articles for article (PubMed ID: 35359852)
21. Real-world characteristics of "super-responders" to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis.
Portacci A; Campisi R; Buonamico E; Nolasco S; Pelaia C; Crimi N; Benfante A; Triggiani M; Spadaro G; Caiaffa MF; Scioscia G; Detoraki A; Valenti G; Papia F; Tomasello A; Scichilone N; Pelaia G; Crimi C; Carpagnano GE
ERJ Open Res; 2023 Sep; 9(5):. PubMed ID: 37908397
[TBL] [Abstract][Full Text] [Related]
22. Improvement of peripheral neuropathy in a patient with antineutrophil cytoplasmic antibody-negative eosinophilic granulomatosis with polyangiitis by additional mepolizumab.
Kai Y; Yoshikawa M; Matsuda M; Suzuki K; Ohara H; Iguchi N; Kasamatsu T; Uno K; Fujioka N; Fujita Y; Muro S
Allergy Asthma Clin Immunol; 2022 Feb; 18(1):14. PubMed ID: 35183225
[TBL] [Abstract][Full Text] [Related]
23. Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study.
Bettiol A; Urban ML; Padoan R; Groh M; Lopalco G; Egan A; Cottin V; Fraticelli P; Crimi C; Del Giacco S; Losappio L; Moi L; Cinetto F; Caminati M; Novikov P; Berti A; Cameli P; Cathébras P; Coppola A; Durel CA; Folci M; Lo Gullo A; Lombardi C; Monti S; Parronchi P; Rivera CM; Solans R; Vacca A; Espígol-Frigolé G; Guarnieri G; Bianchi FC; Marchi MR; Tcherakian C; Kahn JE; Iannone F; Venerito V; Desaintjean C; Moroncini G; Nolasco S; Costanzo GAML; Schroeder JW; Ribi C; Tesi M; Gelain E; Mattioli I; Bello F; Jayne D; Prisco D; Vaglio A; Emmi G;
Lancet Rheumatol; 2023 Dec; 5(12):e707-e715. PubMed ID: 38251561
[TBL] [Abstract][Full Text] [Related]
24. Low-Dose Mepolizumab Effectiveness in Patients Suffering From Eosinophilic Granulomatosis With Polyangiitis.
Vultaggio A; Nencini F; Bormioli S; Vivarelli E; Dies L; Rossi O; Parronchi P; Maggi E; Matucci A
Allergy Asthma Immunol Res; 2020 Sep; 12(5):885-893. PubMed ID: 32638567
[TBL] [Abstract][Full Text] [Related]
25. Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts.
Ghassemian A; Park JJ; Tsoulis MW; Kim H
Allergy Asthma Clin Immunol; 2021 Jan; 17(1):3. PubMed ID: 33407869
[TBL] [Abstract][Full Text] [Related]
26. Successful Treatment of Eosinophilic Granulomatosis With Polyangiitis: A Case of Refractory Peripheral Neuropathy and Comorbid Chronic Progressive Pulmonary Aspergillosis Treated With Mepolizumab.
Sekiya R; Soma T; Nakagome K; Nagata M
Cureus; 2024 Jan; 16(1):e52192. PubMed ID: 38222984
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis.
Steinfeld J; Bradford ES; Brown J; Mallett S; Yancey SW; Akuthota P; Cid MC; Gleich GJ; Jayne D; Khoury P; Langford CA; Merkel PA; Moosig F; Specks U; Weller PF; Wechsler ME
J Allergy Clin Immunol; 2019 Jun; 143(6):2170-2177. PubMed ID: 30578883
[TBL] [Abstract][Full Text] [Related]
28. Mepolizumab as a glucocorticoid-sparing agent in eosinophilic granulomatosis with polyangiitis (EGPA): is a lower dose sufficient?
Vergles M; Matković Z; Lalić K; Trkanjec JT; Tudorić N
J Asthma; 2021 Dec; 58(12):1675-1679. PubMed ID: 32962455
[TBL] [Abstract][Full Text] [Related]
29. Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis.
McBrien CN; Menzies-Gow A
Drugs Today (Barc); 2018 Feb; 54(2):93-101. PubMed ID: 29637936
[TBL] [Abstract][Full Text] [Related]
30. Targeting the interleukin-5 pathway in EGPA: evidence, uncertainties and opportunities.
Berti A; Atzeni F; Dagna L; Del Giacco S; Emmi G; Salvarani C; Vaglio A
Ann Rheum Dis; 2023 Feb; 82(2):164-168. PubMed ID: 36357156
[TBL] [Abstract][Full Text] [Related]
31. Early add-on administration of mepolizumab and intravenous immunoglobulin effective in treating eosinophilic granulomatosis with polyangiitis.
Ikeda T; Komatsu T; Yokoyama K; Takahashi K; Kawakami T
J Dermatol; 2021 Apr; 48(4):529-532. PubMed ID: 33305381
[TBL] [Abstract][Full Text] [Related]
32. Combination of monoclonal antibodies targeting type 2 inflammation for severe asthma and eosinophilic granulomatosis with polyangiitis.
Davanzo F; Marchi MR; Iorio L; Bortoli M; Doria A; Padoan R
Autoimmun Rev; 2024 Mar; 23(3):103503. PubMed ID: 38101691
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis.
Manka LA; Guntur VP; Denson JL; Dunn RM; Dollin YT; Strand MJ; Wechsler ME
Ann Allergy Asthma Immunol; 2021 Jun; 126(6):696-701.e1. PubMed ID: 33548468
[TBL] [Abstract][Full Text] [Related]
34. Real-life evidence of low-dose mepolizumab efficacy in EGPA: a case series.
Detoraki A; Tremante E; Poto R; Morelli E; Quaremba G; Granata F; Romano A; Mormile I; Rossi FW; de Paulis A; Spadaro G
Respir Res; 2021 Jun; 22(1):185. PubMed ID: 34162391
[TBL] [Abstract][Full Text] [Related]
35. Biologics for eosinophilic granulomatosis with polyangiitis.
Caminati M; Maule M; Bello F; Emmi G
Curr Opin Allergy Clin Immunol; 2023 Feb; 23(1):36-43. PubMed ID: 36413432
[TBL] [Abstract][Full Text] [Related]
36. Eosinophilia Induced by Blocking the IL-4/IL-13 Pathway: Potential Mechanisms and Clinical Outcomes.
Olaguibel JM; Sastre J; Rodríguez JM; Del Pozo V
J Investig Allergol Clin Immunol; 2022 Jun; 32(3):165-180. PubMed ID: 35522053
[TBL] [Abstract][Full Text] [Related]
37. Rituximab and mepolizumab combination therapy for glucocorticoid-resistant myocarditis related to eosinophilic granulomatosis with polyangiitis.
Higashitani K; Yoshimi R; Sato Y; Watanabe T; Ihata A
Mod Rheumatol Case Rep; 2022 Jan; 6(1):87-92. PubMed ID: 34473835
[TBL] [Abstract][Full Text] [Related]
38. Anti-IL-5 therapies for chronic obstructive pulmonary disease.
Donovan T; Milan SJ; Wang R; Banchoff E; Bradley P; Crossingham I
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013432. PubMed ID: 33295032
[TBL] [Abstract][Full Text] [Related]
39. Safety and Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis.
Pradhan RR; Nepal G; Mandal S
Pulm Med; 2019; 2019():4376380. PubMed ID: 30941214
[TBL] [Abstract][Full Text] [Related]
40. Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab.
Hillas G; Fouka E; Papaioannou AI
Expert Rev Respir Med; 2020 Apr; 14(4):353-365. PubMed ID: 31958239
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]